头颈部Merkel细胞癌术后单次分割放疗初步研究
中位随访19个月,未见野内局部区域复发,仅1例野外区域复发成功挽救,无MCC相关死亡,未观察到大于1级的放疗相关毒性。
要点
- 术后8 Gy单次分割放疗在头颈部MCC中显示良好的野内局部控制。
- 中位随访19个月未见大于1级放疗相关毒性。
- 初步数据支持单次分割放疗作为老年或体弱患者的替代选择。
核心结论
- 初步数据提示术后8 Gy单次分割放疗可作为头颈部局限期MCC患者传统分割放疗的潜在替代方案。
研究设计与样本
- 以切除日期为起点计算时间至事件,采用死亡作为竞争风险估计野内局部区域复发和野外复发的累积发生率。
主要发现
- 中位随访19个月(范围8-34),无野内局部区域复发。
- 观察到1例野外区域复发并成功挽救,无MCC相关死亡。
- 未观察到大于1级的放疗相关毒性(CTCAE v5)。
临床怎么用
- 对于头颈部局限期MCC患者,若传统分割放疗不可行,可考虑术后8 Gy单次分割放疗。
- 尤其适用于老年或体弱患者,但需在更大 cohort 中验证其持续安全性和有效性。
局限性
- 需要更大 cohort 验证术后单次分割放疗的持续安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Conventionally fractionated, postoperative radiation therapy (cPORT; 50 Gy in 25 fractions) is considered for patients with Merkel cell carcinoma (MCC) to improve locoregional control. However, cPORT is associated with acute toxicity, especially in the head and neck (H&N) region, and requires daily treatments over several weeks. We previously reported high rates of durable local control with minimal toxicity using 8-Gy single-fraction radiation therapy (SFRT) in the metastatic setting. We report early results on a cohort of patients with localized H&N MCC who received postoperative SFRT if a cPORT regimen was not feasible. METHODS AND MATERIALS: Twelve patients with localized MCC of the H&N (clinical/pathologic stages I-II) and no prior radiation therapy to the region were identified from an institutional review board-approved prospective registry who underwent surgical resection followed by postoperative SFRT. Time to event was calculated starting from the date of resection before SFRT. The cumulative incidence of in-field locoregional recurrences and out-of-field recurrences was estimated with death as a competing risk. RESULTS: Twelve patients with H&N MCC were identified with clinical/pathologic stages I-II H&N MCC. Median age at diagnosis was 81 years (range, 58-96 years); 25% had immunosuppression. At a median follow-up of 19 months (range, 8-34), there were no in-field locoregional recurrences. A single out-of-field regional recurrence was observed, which was successfully salvaged. There were no MCC-specific deaths. No radiation-associated toxicities greater than grade 1 (Common Terminology Criteria for Adverse Events v5) were observed. CONCLUSIONS: Preliminary data suggest that SFRT could offer a potential alternative to cPORT to treat the primary site for localized H&N MCC, particularly in elderly or frail patients, with promising in-field local control and minimal toxicity. Further data with validation in larger cohorts are needed to confirm the sustained safety and efficacy of postoperative SFRT.
引用
- Cook MM, Schaub SK, Goff PH, et al. Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck. Adv Radiat Oncol. 2020. PMID: 32838069. doi:10.1016/j.adro.2020.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。